The first session of the COALA Scientific Webinar Series, organized by Work Package 1 (WP1) on 12 March, is now available to watch online.

🎤 Speaker : Célia Delahaye, PhD – Centre de Recherches en Cancérologie de Toulouse (CRCT)
🎙 Moderation : Aurélie Swalduz & Olivier Calvayrac (WP1 Leaders)

🔬 Targeted therapies have revolutionized the standard of care for patients with lung cancer harboring activating driver alterations such as EGFR, ALK, ROS1, or BRAF. Despite impressive initial responses, relapse remains frequent, underscoring the persistence of residual disease. The assessment of minimal residual disease (MRD), particularly through liquid biopsy approaches including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), represents a promising strategy to predict response, detect molecular relapse, and better inform therapeutic decisions. What do we know about MRD, where do we currently stand in integrating MRD into clinical practice, and how can we more effectively leverage its potential to improve patient outcomes ?